Monday 9 November 2026 Export CUE’s income statement to Excel — free account

Cue Biopharma, Inc.

CUE

Healthcare Biotechnology

Cue Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $27.5 million, up 195.7% from fiscal 2024.

Revenue: +166.7%
EPS: −793.2%
Free cash flow: −742.7%

Quarter to June 2026, against a year earlier

18.73 0.72 +4.00%

Follow CUE

Alert me

Market cap: $136.1M
P/E: n/m
Fwd P/E: n/m
Dividend yield: —
F-score: 5/9
ROIC: 0.00%
Net debt / EBITDA: 1.1×
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Net sold: $2.3M
Trades: 6 sells · 1 buy
Ownership: 8.06%

Capital & Financial Ratios $m

Size

Market Cap 136

Revenue ttm 38

Net income ttm (164)

Free cash flow ttm (50)

Net debt Q (17)

Valuation

P/E n/m

Forward P/E n/m

Price / sales 3.2

Forward P/S Powerpack

Price / FCF n/m

Price / book 51.4

Financial health

Current ratio Q 1.3

Debt / equity Q n/m

Interest coverage Q (17,539.0)

Growth

Revenue growth Q +166.7%

Operating income growth Q −915.6%

EPS, this year −197.7%

EPS, next year A +70.2%

Revenue, next year A −43.1%

EPS, past 5 yrs —

EPS, next 5 yrs A +7.2%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates; n/m is not meaningful, as a P/E on a loss. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 5.33%

10-year low 10-year high

P/B against its own 10 years 96.31%

10-year low 10-year high

EV/Sales against its own 10 years 9.21%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	49	23	28	17
Receivables	2	1	6	5
Inventory	—	—	—	—
Other	—	—	2	2
	51	25	37	27

	2023	2024	2025	Q'26
Payables	4	3	4	4
ST’ Debt	4	4	—	—
Other	2	0	5	—
	17	14	13	21

Compound Annual Growth %

	10y	5y	3y
Sales	—	54.16%	180.46%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	14.31%	(19.65%)	(26.17%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY25 Estimate −3.00 Actual −2.10

−5.56 −4.58 −3.61 −2.63 −1.65

Q4 FY24 Beat +0.90

Q1 FY25 Miss −0.91

Q2 FY25 Beat +1.20

Q3 FY25 Beat +0.90

Q3 FY26 — Nov 11

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q4 FY24	−4.80	−3.90	Beat by 0.90
Q1 FY25	−4.20	−5.11	Miss by 0.91
Q2 FY25	−3.90	−2.70	Beat by 1.20
Q3 FY25	−3.00	−2.10	Beat by 0.90
Q3 FY26	−4.04	—	Reports 11 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.08)	(24.14)	—	—	—
’25	(5.11)	(2.70)	(2.10)	0.44	(8.41)
’24	(7.51)	(6.01)	(5.11)	(3.90)	(21.62)
’23	(8.71)	(8.71)	(7.21)	(8.41)	(33.33)
’22	(13.21)	(11.11)	(9.31)	(11.11)	(44.74)
’21	(12.31)	(9.91)	(12.31)	(7.81)	(42.34)
’20	(14.41)	(11.41)	(10.21)	(11.11)	(46.85)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	6	8	—	—	—
’25	0	3	2	22	27
’24	2	3	3	2	9
’23	0	1	2	2	5
’22	1	0	0	0	1
’21	2	3	2	8	15
’20	1	1	1	0	3

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(11)	(29)	—	—	—
’25	(8)	(3)	(9)	(1)	(22)
’24	(10)	(10)	(8)	(9)	(36)
’23	(11)	(10)	(8)	(11)	(40)
’22	(12)	(13)	(7)	(11)	(42)
’21	(12)	(10)	(7)	(11)	(39)
’20	(11)	(7)	(8)	(7)	(32)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(11)	(29)	—	—	—
’25	(8)	(3)	(9)	(1)	(22)
’24	(10)	(10)	(7)	(9)	(36)
’23	(11)	(10)	(8)	(11)	(40)
’22	(12)	(13)	(7)	(11)	(42)
’21	(12)	(10)	(7)	(11)	(40)
’20	(11)	(7)	(8)	(7)	(33)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	1	3	3	15	1	5	9	27	38		+57.5%	16	9	9	(30.1%)
	Gross margin, %	0.00	0.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00		+100.0 pt	Powerpack Cue Biopharma, Inc.’s next three years, line by line Analysts expect revenue to shrink 30.1% a year to 2028 — slower than the 57.5% of the last 7 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(8)	(23)	(38)	(36)	(45)	(44)	(53)	(51)	(41)	(26)	(164)		+14.6%
	EBT margin, %	0.00	0.00	(3,339.34)	(1,049.26)	(1,413.27)	(292.25)	(4,257.83)	(924.10)	(437.97)	(95.03)	(434.50)		(95.0) pt
	Net income	(8)	(23)	(39)	(37)	(45)	(44)	(53)	(51)	(41)	(27)	(164)		+14.8%
Per share, $
Per share, $	Revenue	0.00	0.00	1.70	4.71	3.30	14.34	1.05	3.60	4.95	8.71	5.94		n/m
	Earnings	(30.94)	(65.01)	(58.26)	(49.85)	(46.85)	(42.34)	(44.74)	(33.33)	(21.62)	(8.41)	(26.88)		(13.5%)
	Cash flow	(24.11)	(33.97)	(39.39)	(41.96)	(34.01)	(37.28)	(35.22)	(26.23)	(19.37)	(6.87)	(7.89)		(13.0%)
	Capex	(2.08)	(3.37)	(2.77)	0.11	(0.62)	(0.86)	(0.14)	0.00	0.02	(0.04)	(0.01)		(35.0%)
	Free cash flow	(26.20)	(37.34)	(42.16)	(41.85)	(34.64)	(38.13)	(35.36)	(26.23)	(19.35)	(6.92)	(7.91)		(13.8%)
	Book value	61.31	172.38	50.67	74.37	82.60	62.86	55.33	24.34	9.33	8.38	0.36		(19.8%)
	Shares, m	0	0	1	1	1	1	1	2	2	3	5		+32.7%
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	—	—	0.00	101.09	113.67	23.66	76.10	23.15	6.60	1.20	3.15		43.2
	P/B	—	—	2.78	6.40	4.54	5.40	1.44	3.43	3.51	1.25	51.41		3.6
	EV/Sales	—	—	0.00	85.59	89.03	20.02	22.85	15.75	4.70	0.24	2.74		29.8
	EV/FCF	—	—	(1.96)	(9.64)	(8.48)	(7.53)	(0.68)	(2.16)	(1.20)	(0.30)	(2.05)		(4.0)
Cash, $m
Cash, $m	Operating cash flow	(6)	(12)	(26)	(31)	(32)	(39)	(42)	(40)	(36)	(22)	(50)		+15.4%
	Capex	(1)	(1)	(2)	0	(1)	(1)	0	0	0	0	0		(13.7%)
	Free cash flow	(6)	(13)	(28)	(31)	(33)	(40)	(42)	(40)	(36)	(22)	(50)		+14.4%
Balance, $m
Balance, $m	Working capital	14	60	34	49	71	56	66	34	11	23	5		+5.9%
	Net debt	(15)	(64)	(39)	(54)	(78)	(54)	(66)	(41)	(19)	(28)	(17)		+7.3%
	Shareholders’ equity	15	62	34	55	79	65	66	37	17	26	2		+6.4%
Returns, %
Returns, %	ROA	(64.92)	(55.83)	(69.41)	(62.75)	(52.34)	(48.28)	(60.69)	(66.40)	(86.80)	(71.51)	(459.60)		(6.6) pt
	ROIC	(2,408.88)	0.00	0.00	(2,369.89)	(2,367.67)	(244.49)	0.00	0.00	0.00	0.00	0.00		+2,408.9 pt
	ROE	(69.27)	(60.52)	(81.57)	(82.88)	(67.10)	(61.16)	(80.82)	(98.73)	(149.03)	(121.11)	(1,603.48)		(51.8) pt
People
People	Employees	28	30	47	47	52	59	51	53	41	29	—		+0.4%
	Revenue/emp, $m	0.00	0.00	0.02	0.07	0.06	0.25	0.02	0.10	0.23	0.95	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MSLE Satellos Bioscience Inc.	$152.6M	— (loss-making)	—	—	n/m	−65.66% (below 0%: shrinking)	99.26%	0.00%	Compare
YARW Yarrow Bioscience, Inc	$147.2M	— (loss-making)	— (loss-making)	+40.58% (above 0%: growing)	n/m	+81.56% (above 0%: growing)	100.00%	(3,197.94%)	Compare
CMPX Compass Therapeutics, Inc.	$136.7M	— (loss-making)	— (loss-making)	—	n/m	−26.05% (below 0%: shrinking)	100.00%	0.00%	Compare
CUE Cue Biopharma, Inc.	$136.1M	— (loss-making)	— (loss-making)	+166.66% (above 0%: growing)	n/m	−742.65% (below 0%: shrinking)	100.00%	(1,113.30%)
TARA Protara Therapeutics, Inc.	$135.9M	— (loss-making)	—	—	n/m	−28.10% (below 0%: shrinking)	0.00%	0.00%	Compare
ADAG Adagene Inc. Sponsored ADR	$134.3M	—	— (loss-making)	—	—	−11.08% (below 0%: shrinking)	—	—	Compare
SPRB Spruce Biosciences, Inc.	$133.8M	— (loss-making)	— (loss-making)	−75.86% (below 0%: shrinking)	n/m	−152.10% (below 0%: shrinking)	100.00%	0.00%	Compare
PDSB PDS Biotechnology Corporation	$129.2M	— (loss-making)	—	—	n/m	+69.32% (above 0%: growing)	0.00%	0.00%	Compare
MOLN Molecular Partners AG Sponsored ADR	$119.2M	— (loss-making)	— (loss-making)	−98.86% (below 0%: shrinking)	n/m	+11.07% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$135.1M	—	—	−75.86%	—	−18.56%	99.26%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 21 May 2026

Ownership

Directors and executive officers, together 14.56%

Affiliates of Bleichroeder LP 9.99%

Shao-Lee Lin 8.31%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Cue Biopharma, Inc. (CUE) Latest News

28 Sep

Impact 4 · 5:02 AM · MarketBeat

Cue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU Response

25 Sep

Impact 3 · 11:45 PM · Insider Monkey

Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?

21 Sep

Impact 4 · 6:55 AM · InvestorsHub

Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results

20 Sep

Impact 4 · 6:00 AM

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

14 Aug

Impact 3 · 4:05 PM

Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

3 Aug

Impact 4 · 8:30 AM

Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission

9 Jul

Impact 4 · 9:40 PM

Cue Biopharma Announces $50.0 Million Private Placement

14 May

Impact 3 · 4:07 PM · GlobeNewswire

Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments

30 Apr

Impact 4 · 4:25 PM · GlobeNewswire

Cue Biopharma Announces $30 Million Private Placement

Impact 4 · 4:15 PM · GlobeNewswire

Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody

Impact 4 · 4:05 PM · GlobeNewswire

Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company

22 Apr

Impact 4 · 8:37 AM · GlobeNewswire

Cue Biopharma Announces 1-for-30 Reverse Stock Split

20 Apr

Impact 3 · 10:15 AM

Cue Biopharma (CUE) Appoints Lucinda Warren as Interim President and CEO

15 Apr

Impact 3 · 8:00 AM · GlobeNewswire

Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026

8 Apr

Impact 4 · 8:00 AM · GlobeNewswire

Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement

27 Mar

Impact 4 · 4:05 PM · GlobeNewswire

Cue Biopharma Announces CEO Transition

16 Mar

Impact 4 · 4:05 PM · GlobeNewswire

Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

12 Feb

Impact 3 · 8:00 AM · GlobeNewswireBarchartMT NewswiresMotley Fool

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer

19 Dec

Impact 3 · 8:00 AM · GlobeNewswire

Cue Biopharma Announces Pricing of $10 Million Public Offering

18 Dec

Impact 3 · 4:02 PM · GlobeNewswire

Cue Biopharma Announces Proposed Public Offering

13 Nov

Impact 4 · 1:10 PM · Business Wire

Singapore-based ImmunoScape Pioneers Next-Generation Cell Therapy for Solid Tumors; Announces Key Licensing Deal, New Board and SAB Appointments

12 Nov

Impact 4 · 4:05 PM · GlobeNewswire

Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Impact 3 · 5:25 PM · Zacks

Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue Estimates

6 Nov

Impact 4 · 8:00 AM · GlobeNewswire

Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors

29 Sep

Impact 4 · 9:00 AM · GlobeNewswire

Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates

13 Aug

Impact 4 · 8:00 AM · GlobeNewswire

Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme

12 Aug

Impact 3 · 5:10 PM · Zacks

Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates

Impact 3 · 4:05 PM · GlobeNewswire

Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

16 Jul

Impact 4 · 8:00 AM · GlobeNewswire

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

1 Jul

Impact 4 · 4:05 PM

Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Cue Biopharma, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 21 May 2026

Ownership

Cue Biopharma, Inc. (CUE) Latest News

28 Sep

25 Sep

21 Sep

20 Sep

14 Aug

3 Aug

9 Jul

14 May

30 Apr

22 Apr

20 Apr

15 Apr

8 Apr

27 Mar

16 Mar

12 Feb

19 Dec

18 Dec

13 Nov

12 Nov

6 Nov

29 Sep

13 Aug

12 Aug

16 Jul

1 Jul

Stockrow Weekly